CCM
NVAX icon

CAAS Capital Management’s Novavax NVAX Stock Holding History

CAAS Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000,000
Closed -$10.3M – 851
2022
Q4 		$10.3M Buy
+1,000,000
New +$17.6M 0.62% 29
2022
Q1 		– Sell
-979
Closed -$140K – 854
2021
Q4 		$140K Buy
+979
New +$168K ﹤0.01% 692

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's NVAX Position: Q1 2023 in Review

CAAS Capital Management sold out of Novavax (NVAX) in Q1 2023, closing a stake of 1,000,000 shares — an estimated $10.3M sold.

CAAS Capital Management first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $10.3M in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • CAAS Capital Management reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 1,000,000 Novavax shares in Q1 2023, an estimated $10.3M.
  • CAAS Capital Management first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
  • CAAS Capital Management's Novavax position peaked at $10.3M in Q4 2022.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.